Auditor Mayer Hoffman McCann declines reappointment; FY2022 tax-provision controls deemed ineffective

Forte Biosciences, Inc.

MHM will not stand for re-appointment for FY2024; will cease by new auditor appointment, filing of 2023 10-K, or April 1, 2024.
No disagreements between company and MHM on accounting principles or audit scope for FY2021 and FY2022.
Reportable event: management concluded ineffective controls over completeness and accuracy of annual tax provision in FY2022 10-K.
Audit committee will initiate process to select a new independent registered public accounting firm.
MHM’s audit reports for FY2021 and FY2022 were unqualified, with no adverse opinion or disclaimer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.